Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
NCT06947460Phase 2Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Apr 2025
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GC012 in lupus nephritis (LN), systemic sclerosis (SSc), pulmonary arterial hypertension (PAH) and 1 more, sponsored by Beijing Gaobo Hospital. Primary endpoints: Safety, tolerability, and determination of the optimal biological dose (OBD) and the Phase II recommended dose (RP2D) at 30 days and Overall Remission Rate at 180 days. Started Apr 2025; status: recruiting.
02
Drugs
GC012
03
Conditions
lupus nephritis (LN)systemic sclerosis (SSc)pulmonary arterial hypertension (PAH)autoimmune disease
Beyond the preview
Go deeper on NCT06947460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947460.